MILAN, February 17, 2014 /PRNewswire/ --
BMG Pharma S.r.l. today is pleased to announce that it has signed an exclusive distribution agreement with Samyang Biopharmaceutical Corporation granting them the rights to promote, sell and market its novel mucositis management product GelX® in the territory of South Korea.
BMG Pharma S.r.l will receive an undisclosed down payment from Samyang Biopharmaceutical Corporation who will exclusively market GelX® in South Korea.
GelX® will allow patients to receive the best care possible by using an innovative delivery technology to provide fast pain relief and eliminate swallowing issues and discomfort associated with mucositis related to chemotherapy, radiotherapy, and other pharmacologic therapies.
BMG 's team were the originators of some of the major Rx medical devices in cancer supportive care including Radiation Dermatitis and Xerostomia and we are sure we are providing the market with a new generation of innovative products for support of cancer patients and we are very pleased of the commitment from a major company like SAMYANG for GelX® said Marco Mastrodonato, President and CEO of BMG Pharma S.r.l.
We are very pleased to work with BMG Pharma S.r.l. to launch GelX® in the South Korean market, said Cheolho Kwak, President of Samyang Biopharmaceutical Corporation, because the delivery technology associated with GelX® is a significant breakthrough in ease of use and compliance associated with patients presenting with especially chemotherapy/radiotherapy-induced Oral Mucositis.
BMG Pharma S.r.l. granted the exclusive distribution rights to Samyang Biopharmaceutical Corporation for GelX® in two different formulations : GelX® oral gel 300 ml and GelX® Oral spray 100 ml.
Mucositis and stomatitis are an inflammation of the oral cavity, normally accompanied by erythematous lesions and sometimes by ulcerative lesions that are particularly painful, making chewing and swallowing difficult.
GelX® Oral Gel and GelX® oral Spray have a mechanical action indicated for the management and relief of pain by adhering to the mucosal surface of the mouth, soothing the lesions caused by chemotherapy and/or radiation therapy.
GelX®, in both formulations, is designated to benefit patients by improving the convenience, efficacy and compliance over existing marketed products.
About Samyang Biopharmaceutical Corporation
Samyang Biopharmaceutical Corporation is Samyang group's fully owned subsidiary company engaged in research and
development of innovative technology platforms for drug
delivery and novel application of its expertise in biopolymers
for developing pharmaceuticals and biomedical devices. Samyang Biopharmaceutical Corporation is currently striving to become leading specialty pharmaceutical company in Korea with primary focus on the development and commercialization of oncology and related pharmaceutical products using in-house R&D activities and licensing deals.
For additional information, please visit us at http://www.samyangbiopharm.com.
About BMG Pharma S.r.l.
BMG Pharma S.r.l. is a Specialty Pharmaceutical Company with head office in Milan, Italy, leveraging its proprietary technology to develop products that address unmet needs of patients. The Company is currently focused on cancer supportive care, dermatology gynecology, ENT and oral health. BMG Pharma S.r.l. is dedicated to helping patients, pharmacists and physicians by providing valuable and innovative products to the market.
For press releases and other company information, visit: http://www.bmgpharma.com
Contact: Loredanan Galli, +39(02)91321756, firstname.lastname@example.org
SOURCE BMG Pharma S.r.l.